Risk classification in mild cognitive impairment patients for developing alzheimer's disease

Journal of Alzheimer's Disease

Volumn 30, Issue 2, 2012, Pages 367-375

  Zhou, Bin ^a   Nakatani, Eiji ^a,b   Teramukai, Satoshi ^b   Nagai, Yoji ^a   Fukushima, Masanori ^a  

^a FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alzheimer's disease; conversion; mild cognitive impairment; risk classification

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CEREBROSPINAL FLUID; DISEASE COURSE; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; TASK PERFORMANCE; TEMPORAL LOBE;

EID: 84861549112     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112117     Document Type: Article

References (29)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Alzheimer's Disease International Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
2. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cum-mings JL, DeKosky ST (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review), Report of the quality standards subcommittee of the American academy of neurology. Neurology 56, 1133-1142.
3. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6, 108-119.
4. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6, 67-77.
5. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
6. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Schel-tens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
8. Petersen RC (2011) Clinical practice. Mild cognitive impairment. N Engl J Med 364, 2227-2234.
9. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, Whitwell JL, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW (2008) The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27, 685-691. (Pubitemid 351508080)
10. Fennema-Notestine C, McEvoy LK, Hagler DJ Jr, Jacob-son MW, Dale AM, The Alzheimer's Disease Neuroimaging, Initiative (2009) Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp 30, 3238-3253.
11. Fischl B, Sereno MI, Dale AM (1999) Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 9, 195-207. (Pubitemid 29369875)
12. Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 97, 11050-11055.
13. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968-980. (Pubitemid 44183792)
14. LeBlanc M, Crowley J (1993) Survival trees by goodness of split. J Am Stat Assoc 88, 457-467.
15. Cox DR (1972) Regression models and life-tables. JR Stat Soc 34, 187-220.
16. Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15, 361-387. (Pubitemid 26072233)
17. Lakatos E (1988) Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44, 229-241. (Pubitemid 18098824)
18. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H, North American Alzheimer's Disease Neuroimaging Initiative. (2010) Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neu-robiol Aging, doi: 10.1016/j.neurobiolaging.2010.10.019.
19. Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS (2010) Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133, 3336-3348.
20. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Tro-janowski JQ (2011) Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging 32, 2322. e19-e27.
21. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging, Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
22. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Par-netti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
23. Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC (2011) Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 76, 501-510.
24. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta (42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65, 176-183.
25. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
26. Schott JM, Bartlett JW, Fox NC, Barnes J, Alzheimer's Disease Neuroimaging Initiative Investigators (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Afj 1-42. Ann Neurol 68, 825-834.
27. Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB (2010) Alzheimer's Disease Neuroimaging Initiative Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 31, 1443-1451.
28. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6, e16032.
29. Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: Insights into memory loss in MCI. J Alzheimers Dis 23, 257-269.